Accelerated myocardial fibrosis in young to middle-aged patients with hypertrophic cardiomyopathy

Shiro Nakamori1, Ethan J Rowin2, Jennifer Rodriguez3

  • 1Departments of Medicine (Cardiovascular Division) Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA; Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, Tsu, Japan.

Insights

Younger hypertrophic cardiomyopathy (HCM) patients show faster late gadolinium enhancement (LGE) progression than older adults. This highlights the need for regular cardiovascular magnetic resonance (CMR) monitoring in younger HCM individuals to track fibrosis development.

Area of Science:

  • Cardiology
  • Cardiovascular Imaging
  • Medical Research

Background:

  • Late gadolinium enhancement (LGE) on cardiovascular magnetic resonance (CMR) indicates increased sudden cardiac death risk in hypertrophic cardiomyopathy (HCM).
  • Longitudinal changes in LGE extent and their association with age are not well understood in HCM patients.
  • Assessing age-specific LGE progression is crucial for risk stratification in HCM.

Purpose of the Study:

  • To investigate age-specific differences in the progression of late gadolinium enhancement (LGE) in hypertrophic cardiomyopathy (HCM).
  • To compare LGE progression rates between young to middle-aged adults (20-59 years) and older adults (≥60 years) with HCM.

Main Methods:

  • Retrospective analysis of 102 HCM patients with serial CMR studies over a median of 3.7 years.
  • Semiautomated quantification of LGE extent relative to left ventricular (LV) mass.
  • Comparison of LGE progression rates between age groups (<60 years and ≥60 years).

Main Results:

  • LGE was present at baseline in 60% of HCM patients, averaging 4.8% of LV mass.
  • At follow-up, 87% of patients with baseline LGE showed an increase, reaching 7.7% of LV mass.
  • Patients under 60 years had a significantly higher rate of LGE progression (≥1%/year) compared to those 60 and older (25% vs. 7%, p=0.03).

Conclusions:

  • Progressive fibrosis, indicated by LGE, is more common in younger to middle-aged adults with HCM.
  • Younger age (<60 years) and baseline LGE extent (≥10%) are predictors of accelerated LGE progression.
  • Serial CMR is important for monitoring LGE progression in younger HCM patients.
Abstract